OncosphereESMO 2026: what changed this week (2–6 November)
Between 2 and 6 November 2026 the Oncosphere ESMO Madrid coverage moved from four long trial posts to a connected package: Presidential Symposium write-ups, a simultaneous NEJM pair outside the Presidential slot, a one-page hazard-ratio forest plot, and a ten-question quiz. This page is a text map of what is now on the site — not new primary data. Every figure below is copied from the linked Oncosphere pages, which already cite NEJM papers and sponsor releases.
What is live now
- Presidential Symposium I — INTerpath-001, VOLGA, DeLLphi-305, DASL-HiCaP — four LBA phase 3 summaries (Madrid, 24 Oct)
- Presidential Symposium II — Krascendo 1, SAFFRON, CLARITY-Gastric 01, HARMONi-GI1 — four LBA phase 3 summaries (Madrid, 25 Oct)
- NEJM companion — HEALER and OptiTROP-Lung06 — two China-run phase 3s published with ESMO, not in the Presidential slot
- Forest plot — Hazard ratios for all 10 trials — one-page visual of headline and OS HRs with 95% CIs
- Trial quiz — 10 interactive questions — self-test keyed to the three trial pages
- Trial matching game — match 10 trials to disease or regimen — click-to-pair self-test keyed to the same pages
- Hub — ESMO 2026 Madrid hub — index of all of the above
How the ten trials fit together
Presidential Symposium I (LBA1–4) was about curative-intent and first-line maintenance wins with mixed maturity on overall survival:
- INTerpath-001 (adjuvant resected stage IIB–IV melanoma): individualised mRNA neoantigen therapy (intismeran autogene) + pembrolizumab improved RFS — HR 0.58 (95% CI 0.45–0.75); 24-month RFS 82.2% vs 70.0%. OS immature (HR 0.77, not significant). Benefit appeared after the six-month immunisation course. Source page: Presidential Symposium I (Merck/Moderna release; accepted by NEJM).
- VOLGA (cisplatin-ineligible/refusing MIBC): perioperative durvalumab + neoadjuvant enfortumab vedotin cut event risk — EFS HR 0.51 (0.38–0.67); OS HR 0.58 (0.40–0.83). 24-month EFS 63.5% vs 45.1%; pCR 45% vs 10%. Published in NEJM with ESMO (Powles et al.).
- DeLLphi-305 (ES-SCLC first-line maintenance): tarlatamab + durvalumab vs durvalumab alone — median OS 21.1 vs 12.7 months, OS HR 0.42 (0.32–0.54); PFS HR 0.34. Published in NEJM (Pérol et al.).
- DASL-HiCaP (very high-risk localised prostate, with RT + ADT): darolutamide improved MFS — HR 0.42 (0.27–0.66); 4-year MFS 95% vs 88%. OS not significant (HR 0.88). Abstract/sponsor data so far.
Presidential Symposium II (LBA5–8) was different: every trial beat an active control on overall survival, not placebo:
- Krascendo 1 (pretreated KRAS G12C NSCLC): divarasib vs sotorasib/adagrasib — PFS 9.8 vs 5.7 months (HR 0.58); OS 17.7 vs 12.0 months (HR 0.56). NEJM simultaneous (Skoulidis et al.).
- SAFFRON (EGFR-mutant NSCLC progressing on osimertinib with MET overexpression/amplification on post-progression biopsy): osimertinib + savolitinib vs platinum–pemetrexed — PFS 7.6 vs 5.4 months (HR 0.55); final OS 17.8 vs 12.9 months (HR 0.68). NEJM.
- CLARITY-Gastric 01 (CLDN18.2+ gastro-oesophageal, ≥1 prior line): sonesitatug vedotin vs investigator’s choice — dual-primary ITT PFS not met (HR 0.77); OS benefit driven by 3L+ — 10.0 vs 5.0 months (HR 0.47). AstraZeneca release / OncLive detail.
- HARMONi-GI1 (first-line biliary, all-China): ivonescimab + GemCis vs durvalumab + GemCis — OS 14.9 vs 12.1 months (HR 0.75); PFS 8.4 vs 5.8 months (HR 0.61). First phase 3 to beat the TOPAZ-1 regimen on the figures cited on the site.
Outside the Presidential slot but into NEJM — the 2 November note on HEALER and OptiTROP-Lung06:
- HEALER (first-line HER2+ advanced breast): anbenitamab + albumin-bound docetaxel vs THP — 24-month PFS 58.5% vs 34.4%; HR for progression or death 0.46 (0.37–0.56). OS immature. China-only; two variables changed at once (bispecific + nab-docetaxel).
- OptiTROP-Lung06 (PD-L1 TPS <1% non-squamous NSCLC, driver-negative): sacituzumab tirumotecan + pembrolizumab vs chemo + pembrolizumab — median PFS 15.0 vs 5.7 months (HR 0.49). OS immature (descriptive HR 0.58).
Together these ten trials cover melanoma adjuvant mRNA, perioperative bladder ADC–IO, SCLC bispecific maintenance, high-risk prostate ARPI intensification, next-generation KRAS G12C and EGFR/MET combinations, a CLDN18.2 ADC, a PD-1×VEGF bispecific in biliary cancer, a HER2 biparatopic first-line challenge to THP, and a TROP2 ADC–IO challenge to chemo-IO in PD-L1-negative lung cancer.
What the forest plot and quiz add
The forest-plot page (3 Nov) puts the same hazard ratios on one educational SVG: headline end points (RFS/EFS/OS/MFS/PFS as reported) and a separate OS panel. Grey rows flag end points that did not meet significance or were not formally tested (for example CLARITY ITT PFS, and immature OS for INTerpath-001 and DASL-HiCaP). It is for scale and memory, not head-to-head comparison — populations, end points and follow-up differ.
The trial quiz (2 Nov) asks ten questions keyed to those same pages (setting, timing of benefit, EFS/OS HRs, MET-altered eligibility, CLDN18.2 OS locus, HEALER/OptiTROP PFS). Answers stay in the browser; every explanation links back to the source post.
Reading order if you are catching up
- Skim this page for the map.
- Open Symposium I, then Symposium II, then the HEALER/OptiTROP note for tables, toxicity and regulatory caveats.
- Use the forest plot to lock the HRs visually.
- Run the quiz once, or try the matching game.
Hub index: ESMO 2026 Madrid. Related: FDA decisions to watch in November 2026 (ivonescimab, neladalkib, giredestrant PDUFA dates — separate from the Madrid LBAs).